Jan Schmidt-brand

Biography

  Dr. Jur. Jan Schmidt-Brand has been the Chief Financial Officer of Wilex AG since September 01, 2012 and serves as its Member of The Executive Management Board and Chief Executive Officer. Dr. Jur. Schmidt-Brand has been Chief Executive Officer of Heidelberg Pharma AG since December 2006 and has been its Chief Financial Officer since September 2001. He has been Managing Director of WILEX's subsidiary Heidelberg Pharma GmbH since September 1, 2012. He served as Executive Vice President of Administration at Heidelberg Pharma AG. He held several positions at the BASF Group for a total of eight years, as an executive in the central tax department with a general commercial power of attorney ('Prokurist'). He serves as Head of the Finance and Tax working group. Dr. Jur. Schmidt-Brand served as an Executive Vice President of Finance at Heidelberg Pharma AG. He served as Managing Director of Heidelberg Pharma Holding GmbH & Co. KG. Prior to Heidelberg, he served as Chief Financial Officer since September 2001 and Managing Director of EBEWE Arzneimittel GmbH, an Austrian pharmaceutical firm within BASF Pharma from 1997 to 2001. In EBEWE Arzneimittel GmbH, he managed the marketing, sales, finance and administrative areas and was responsible for the successful launch of the innovative antiobesity drug Reductil™ and the redesign of EBEWE's strategy within BASF Pharma. He was employed at BASF AG and Knoll AG in various legal, tax and controlling roles and was engaged in several corporate restructuring as well as merger and acquisition projects. He is a member of the Board of BioDeutschland. Dr. Jur. Schmidt-Brand received degrees in law and business administration from the University of Bayreuth, Mannheim and Geneva, respectively. He holds a doctorate in law.  

Research Interest

 business